Assessment of IBD Medications on COVID-19 Outcomes
Researchers sought to assess the association of IBD medications and their combinations on the risk of severe COVID-19 outcomes.
Researchers sought to assess the association of IBD medications and their combinations on the risk of severe COVID-19 outcomes.
Researchers’ goal was to employ fMRI to identify differential brain responses to noxious stimuli in patients with chronic pain while adhering to best practices for neuroimaging meta-analyses.
Recently updated diagnostic criteria for fibromyalgia that reduce the underdiagnosis in men had not been implemented during these studies.
Ibsrela is a sodium/hydrogen exchanger 3 (NHE3) inhibitor.
Researchers evaluated the response of rifaximin therapy in patients with IBS-D with abdominal pain symptoms.
A 2-week course of treatment with rifaximin for diarrhea-predominant irritable bowel syndrome was found to improve abdominal pain symptoms.
Public-private partnership initiative develops core diagnostic criteria for abdominal, pelvic, and urogenital pain associated with irritable bowel syndrome.
The FDA has accepted the supplemental New Drug Application for Trulance for the treatment of irritable bowel syndrome with constipation.
The efficiency of self-administered hypnotherapy is equivalent to that of in-office hypnotherapy in relieving pediatric irritable bowel syndrome or functional abdominal pain.
Probiotics may alleviate pain in the short-term in children with recurrent abdominal pain.